Multicentre, Randomised, Double-blind, Phase III Trial to Investigate the Efficacy and Safety of Oral Nintedanib Plus Docetaxel Therapy Compared to Placebo Plus Docetaxel Therapy in Patients With Stage IIIB/IV or Recurrent, Adenocarcinoma Subtype Non-small Cell Lung Cancer After Failure of First Line Chemotherapy
Phase of Trial: Phase III
Latest Information Update: 24 Mar 2017
Price : $35 *
At a glance
- Drugs Nintedanib (Primary) ; Docetaxel
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms LUME-Columbus
- Sponsors Boehringer Ingelheim
- 26 Apr 2016 Status changed from completed to discontinued.
- 07 Jan 2016 Status changed from active, no longer recruiting to completed reported by ClinicalTrials.gov.
- 02 Sep 2015 Planned End Date changed from 1 Dec 2019 to 1 Dec 2015 as reported by ClinicalTrials.gov.